Abstract
Objective To investigate the expression of miRNA-22(miR-22) in serum of patients with lung cancer and its value in the diagnosis of lung cancer. Methods Serum samples were collected from total 116 non-small cell lung cancer (NSCLC) cases, 10 small cell lung cancer (SCLC) cases and 152 cancer-free controls.The expression of serum miR-22 was evaluated in all the samples by quantitative real time RT-PCR.Receiver operating characteristic curve (ROC) analysis was used to evaluate the impact of miR-22 on its diagnostic value for lung cancer. Results The relative expressions of serum miR-22 in NSCLC patients, SCLC patients and cancer-free controls were 1.63±1.43, 1.10±1.64 and -0.02±1.31, respectively.The expression of miR-22 in NSCLC patients was higher than that in SCLC patients and cancer-free controls (F=49.35, P 0.05). Moreover, the expressions of miR-22 in patients with stage Ⅰ, Ⅱ and Ⅲ/Ⅳ NSCLC were 1.65±1.36, 1.49±1.60 and 1.00±1.42 respectively and they were all higher than cancer-free controls (all P 0.05). There was no significant difference of miR-22 expression among different pathological subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell lung cancer(all P>0.05). ROC analyses were performed using cancer-free group as negative control and the area under curve values of serum miR-22 were ranged between 0.72-0.82 in either NSCLC group, or its histological subtypes or different stages.When optimal cut-offs were selected the sensitivities and specificities were 70.59%-75.32% and 54.61%-73.03% respectively. Conclusions These data indicated serum miR-22 is of great significance for early diagnosis of lung cancer.As a non-invasive detection method, microRNA-22 is expected to become a new indicator for early diagnosis of lung cancer. Key words: Carcinoma, non-small-cell lung; Tumor makers, biological; Early diagnosis; miR-22
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call